FDA Delays Decision on Actos Replacement
Last week, Japan-based Takeda Pharmaceutical Co Ltd, makers of the drug Actos, announced that the FDA will extend its review of the company’s drug alogliptin.
Last week, Japan-based Takeda Pharmaceutical Co Ltd, makers of the drug Actos, announced that the FDA will extend its review of the company’s drug alogliptin. Alogliptin, a diabetes medication, was expected to be the successor to Takeda’s top-selling drug Actos. Before Takeda lost its patent protection on Actos, the type-2 diabetes treatment had been linked to an increased risk of bladder cancer in studies. In response, the FDA issued a warning to doctors who prescribed Actos to patients.
Seeger Weiss LLP, a national plaintiffs’ law firm, has been actively investigating the link between Actos and bladder cancer. If you believe you or someone you know developed bladder cancer as a result of taking Actos, the firm’s drug injury practice will review your case for free. Contact them here.
In a Feb. 1 settlement, German automaker Volkswagen agreed to fully compensate American consumers who purchased 3.0-liter diesel engine vehicles equipped with the company’s rigged “clean diesel” emissions testing devices. The company [...]February 3, 2017 By: Seeger Weiss read more
On January 24, the Supreme Court of New Jersey unanimously restored a $25 million verdict for a Seeger Weiss LLP client who sued the drug manufacturer Hoffmann-La Roche after suffering side effects [...]January 30, 2017 By: Seeger Weiss read more